Modern Medicine publishes informative article on the clinical benefits of modulating the microbiome authored by our CEO Dr James McIlroy. In the article Dr McIlroy discusses the clinical benefits of modulating the microbiome, which are leading to new medical products and inspiring a behavioral shift in gut health.

‘Encapsulating and Enhancing the Microbiome - A New Era for Microbe-Based Medicines’ – EnteroBiotix article features in the European Biopharmaceutical Review

Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome

Originally published in Fierce Biotech. EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed.

Originally published in Fierce Biotech. EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health.

Originally published in Endpoint News. Scottish biopharma Enterobiotix today announced the closing of its $21.5 million Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and support its product development and manufacturing capabilities.